The small exploratory analysis also showed a trend towards improved ORR and longer PFS in patients with higher (≥1%) programmed death ligand 1 (PD-L1) expression on tumor cells 13 .
← all excerpts
Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab.
1
—
—